-
North Korea test-fires two new air defence missiles: KCNA
-
Sinner, Sabalenka chasing rare repeats as US Open gets underway
-
Venezuela rallies militia volunteers in response to US 'threat'
-
Musk's megarocket faces crucial new test after failures
-
UK's mass facial-recognition roll-out alarms rights groups
-
Home hope Henderson, Aussie Lee share Canadian Women's Open lead
-
Fucsovics holds off van de Zandschulp for ATP Winston-Salem crown
-
Fleetwood, Cantlay share PGA Tour Championship lead
-
Argentina stun All Blacks with historic 29-23 upset win
-
France begin Women's Rugby World Cup with hard-fought win over Italy
-
Barca complete late comeback win as Atletico drop more points in Liga
-
Alcaraz targeting 'unbelievable' Sinner at US Open
-
Swiatek plays down favorite status ahead of US Open
-
De Bruyne strikes in Napoli's strong start as Modric's Milan sank by Cremonese
-
Springboks back in contention after win - Erasmus
-
Cirstea downs Li to claim WTA Cleveland crown
-
Nigeria says killed over 35 jihadists near Cameroon border
-
Sri Lanka ex-president rushed to intensive care after jailing
-
Russia claims more Ukraine land as hopes for summit fade
-
Atletico still without Liga win after Elche draw
-
Schell shock as six-try star leads Canada to 65-7 World Cup hammering of Fiji
-
Gyokeres scores twice but injuries to Saka, Odegaard sour Arsenal rout of Leeds
-
Leverkusen stumble in Ten Hag Bundesliga debut, Dortmund collapse late
-
Man City revamp rocked by Spurs, Arsenal thrash Leeds
-
Gyokeres scores twice as Arsenal rout Leeds
-
De Bruyne strikes in Napoli's strong start to Scudetto defence at Sassuolo
-
Seoul says fired warning shots after North Korean troops crossed border
-
McGhie the hat-trick heroine as Scotland overwhelm Wales in Women's Rugby World Cup
-
'It's in my DNA': Williams relishes US Open return at 45
-
Portugal suffers new wildfire death as Spain beats back blazes
-
Pollard steers Springboks to victory over Wallabies
-
Aubameyang stars as Marseille end chaotic week on five-goal high
-
US govt wants migrant targeted in crackdown deported to Uganda: lawyers
-
Man City revamp rocked by Spurs, Villa beaten at Brentford
-
Philipsen wins Vuelta a Espana opening stage
-
Crystal Palace's Eze returns to boyhood club Arsenal
-
Reyna trades Dortmund for Gladbach chasing 'new chapter'
-
Leverkusen stumble in Ten Hag Bundesliga debut
-
'Far too late': Palestinians despair after UN declares famine in Gaza
-
Diamond sparkles for Irish training icon Mullins in the Ebor
-
Tottenham's new-found desire to defend delights Frank
-
Man City troubles reappear as solid Spurs go top
-
Marquez sweeps to victory in Hungary to bolster title lead
-
Australia start Women's Rugby World Cup with record 73-0 rout of Samoa
-
Man City's old problems rear their head as Tottenham ease to victory
-
Revenge off the menu for Ginting at badminton world championships in Paris
-
Guinea's junta suspends three main political parties
-
Bosnia's Serb statelet calls referendum on verdict against leader
-
'Uncle Marc' Guehi credits family and Swansea for Palace starring role
-
Berlin's 'Moors' Street' renamed after years of controversy
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
D.Kaufman--AMWN